3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
6
Other hematologic neoplasm
3
Myeloid
2
Dermatologic
2
CNS
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other neoplasm
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
pembrolizumab
77
Injections
67
Carboplatin
38
Nivolumab
30
Pemetrexed
29
Cisplatin
29
Cyclophosphamide
25
Specimen Handling
24
Interviews as Topic
24
atezolizumab
21
tislelizumab
20
Bevacizumab
20
Paclitaxel
19
fludarabine
16
Standard of Care
16
Practice Guidelines as Topic
16
Docetaxel
16
Ipilimumab
15
toripalimab
14
Educational Status
14
Cetuximab
14
Fluorouracil
13
Oxaliplatin
12
Etoposide
12
olaparib
11
durvalumab
11
Methods
11
Gemcitabine
11
Early Intervention, Educational
11
Drug Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Influenza Vaccines
×
Other solid neoplasm
×
1 year
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled